SUMMARY A new method is described for separating free 35SO4-from 35SO4 labelled groteoglycans synthesised by rabbit articular chondrocytes cultured in the presence of excess 4 The procedure uses the low solubility product of barium sulphate to remove, by precipitation, free 35SO4-from culture medium. Optimum recovery of 35so4 labelled proteoglycans was achieved after papain digestion to release 35SO4-glycosaminoglycans, and addition of chondroitin sulphate before the precipitation step. Using this assay, we studied the effect of six drugs-indomethacin, diclofenac, sodium pentosan polysulphate, glycosaminoglycan polysulphate ester, tiaprofenic acid, and ketoprofen-on the secretion into the medium of labelled proteoglycans by lapine chondrocytes. The six drugs were tested at 0< 1, 1, 10, 50, and 100
cartilage metabolism, but it is often difficult to assess the validity of such claims because of the limitations of the methods used. Ideally the influence of a drug on cartilage cells should be monitored at different drug concentrations, over different time periods, and under carefully controlled conditions, but in many cases these criteria are not fully observed. The most convenient means of assessing the effects of drugs on chondrocytes is by in vitro assays. Although this approach has its shortcomings, it can provide a primary screening system, which can be followed up by animal experiments. Measurement of proteoglycan production by cartilage explants or chondrocyte monolayers generally involves pulsing the cultures with 35so--to radiolabel the newly synthesised proteoglycans. This method, however, requires the subsequent separation of the resulting 35 o4 labelled proteoglycans from the large amounts of unincorporated 35SO4 -. This may be achieved by removal of the free 35so--by gel filtration chromatography of each sample,2 exhaustive dialysis of individual samples,3 or papain digestion and cetylpyridium chloride precipitation of the 35S04-glycosaminoglycans. 4 These methods are time consuming and tedious and, in the latter method in particular, the number of steps involved could result in significant cumulative experimental errors. In the present study we Medium was decanted from confluent chondrocyte cultures, cells were washed with two 5 ml volumes of PBS, and then 3 ml of 0-2% trypsin, 0-1% edetic acid (Ajax Chemical Company, Sydney, Australia) in PBS was added, and cultures were incubated at 37°C for two to three minutes until the cells detached. The cells were aspirated and washed in three 15 ml volumes of F12-FCS, then counted, and the concentration adjusted to 2xi05 cells/ml. The cell suspension was dispensed into the wells (105 cells/well in 0.5 ml) of 24-well plates (Flow Laboratories, McLean, Va, USA). At this plating density the cells had attached to form confluent monolayers after an overnight incubation. The medium was changed and each well received 450 ,ul of F12-FCS containing 4-3 x 106 disintegrations per minute 4 (92-5 kBq/well) (New England Nuclear Corp, Bedford, MA, USA). The various drugs were dissolved and appropriately diluted in serum free Ham's F12 medium and delivered to the wells in 50 RI volumes, to give final volumes in the wells of 500 Rl and the desired final drug concentrations of 0, 0-1, 1, 10, 50, and 100 ,ug/ml. Four replicate wells were used for each drug concentration. Sufficient F12-FCS plus 35SO4 -was prepared in a single batch for the experiment to ensure that all wells were exposed to an equal concentration of 35so4-at each medium change. Medium was changed and fresh drug solutions were added after two, four, and six days of culture. At these medium changes and on day 8 when the experiment was terminated the exhausted medium was pipetted from each well into tubes and stored for assay.
35S04-PROTEOGLYCAN ASSAY
The level of secretion of labelled proteoglycans by the chondrocytes was measured by separating free (unincorporated) 4 from 35so4 labelled proteoglycans, as described below. The principle of the separation method is based on the insolubility of barium sulphate (BaSO4). The chondrocyte culture supernatants (500 RI), which were collected into 75 x 10 mm plastic tubes (Edwards Medical Supplies, Narellan, NSW, Australia), were subjected to papain digestion to release glycosaminoglycans. The stock solution used was 2 5 mg/ml papain (crude powder) (Sigma Chemical Co, MO, USA), 7-9 mg/ml cysteine-HCl ( 4 (185 kBq/ml) for 48 hours. The medium was removed and concentrated to approximately 5 ml using an Amicon YM10 membrane (Amicon Corp, Danvers, MA, USA). The sample was then applied to a 1 6x90 cm Sepharose CL2B column (Pharmacia South Seas Pty Ltd, Sydney, NSW, Australia), which had been precalibrated with DNA (VO) and Na235SO4 (Vt). The column was eluted with 0.5 M sodium acetate (pH 6.8) at a flow of 10 ml/h and fractions (3.0 ml) monitored for radioactivity. The 35SO4-proteoglycans eluted at VO as a single peak of aggregated proteoglycans and free 35so4 -eluted at Vt. The VO fractions were pooled and used as a source of purified 35S04-proteoglycans to validate the proteoglycan assay. The specific activity of the 35SO4-proteoglycan preparation determined after hexuronate analysis5 was 15 000 cpm/4g hexuronic acid.
STATISTICAL ANALYSIS
The data generated on the effects of each drug studied on proteoglycan synthesis were analysed by two factor analysis of variance. Each analysis had six rows (drug concentrations: 0, 0-1, 1, 10, 50, and 100 ig/ml) and four columns (culture periods: day 0-2, 2-4, 4-6, and 6-8) and tested three null hypotheses: (1) that there was no significant difference in the proteoglycan synthesis of cultures exposed to any of the six drug concentrations (difference between rows); (2) that there was no significant difference in the proteoglycan synthesis of cultures during any of the four culture periods (difference between columns); and (3) that the 'dose-reponse' to the drug was not significantly different at any of the four culture periods (interaction). As all the null hypotheses proposed were rejected and the differences were highly significant (see Figs 1-6), the significant differences between all 24 means (6x4) were determined using the Student-Neuman-Keules test and the 5% level of the Q distribution.6
Results

PROTEOGLYCAN ASSAY
To separate free 35so--from 35S04-proteoglycan in the chondrocyte culture supematant we used the very low solubility product of BaSO4 (1-2x10-1) relative to the moderate solubility of the glycosaminoglycan barium salts. Table 1 DAY 0-2 drug proteoglycan secretion was inhibited. This significant diminution of proteoglycan secretion at high concentrations of sodium pentosan polysulphate, unlike glycosaminoglycan polysulphate ester, persisted throughout the experiment. Like glycosaminoglycan polysulphate ester, sodium pentosan polysulphate at 0 1 and 1 [ig/ml stimulated proteoglycan secretion from day 2 onwards, the maximum stimulation being produced by 1 ig/ml at each two day culture interval. The response with time to 10 tLg/ml sodium pentosan polysulphate was variable, the effect being stimulatory during days 2-4, inhibitory during days 4-6, and the same as that of the controls on days 0-2 and days 6-8.
Indomethacin
The pattern of response of the chondrocyte cultures to indomethacin was consistent over each culture interval (Fig. 3) . Proteoglycan secretion was unaffected by concentrations of this drug of 0*1, 1, and 10 RIg/ml, but was profoundly inhibited at 50 and 100 I.g/ml. By days 4-6 35S04-proteoglycan secretion in the presence of 100 ,Ig/ml indomethacin was essentially abolished, being reduced to the level of background disintegrations per minute.
Diclofenac
The pattern of proteoglycan secretory activity of chondrocytes cultured in medium containing diclofenac was found to be almost identical to that of cultures exposed to indomethacin (Fig. 4) . Diclofenac at 0-1, 1, and 10 jig/ml did not significantly suggests that diclofenac at 50 Itg/ml was slightly more inhibitory than indomethacin at 50 ig/ml. Ketoprofen This drug elicited very little effect on proteoglycan secretion by rabbit chondrocytes over the concentration range studied (Fig. 5) . During days 0-2 all cultures secreted the same amount of 35S04-proteoglycan. The same was observed during days 6-8. On days 4-6 chondrocytes cultured in the presence of 100 gg/ml ketoprofen secreted significantly less proteoglycan than controls, but the magnitude of the reduction was modest. On days 2-4, when secretion levels were highest overall, a statistically significant diminution of proteoglycan secretion relative to control values resulted from both 50 and 100 [ig/ml ketoprofen, but the diminished levels of proteoglycan secretion resulting from these two drug concentrations were not distinguishable statistically from each other.
Tiaprofenic acid
The proteoglycan secretion of articular chondrocytes cultured in the presence of tiaprofenic acid was broadly similar to that observed with ketoprofen, but concentration effects were more pronounced ( Fig. 6 ). During days 0-2 there was a slight but significant reduction in proteoglycan secretion at concentrations of 10, 50, and 100 Fg/ml, but the proteoglycan levels produced at these three drug concentrations were not different from one another. During the two to four day culture period the drug at 0*1, 1, and 10 jig/ml had no significant effect on secretion compared with the controls, whereas 50 Rg/ml and 100 ILg/ml tiaprofenic acid reduced proteoglycan secretion. This pattern was repeated in the following culture period (days 4-6) and maintained for days [6] [7] [8] . In this last culture period, however, the magnitude of the reduction in the level of proteoglycan secretion at 50 and 100 ,ug/ml tiaprofenic acid, though still significant, was only slight. into rabbit chondrocyte cultures and reported that the presence of 5 Rg/ml of diclofenac had no effect. 14 In all these studies proteoglycan synthesis was measured at a single timepoint only after a period of exposure to the drug. In addition, the different sources of cartilage, the variable periods of exposure to the drug, the widely varying range of concentrations selected for study, and other aspects of the experimental designs have all contributed to the confused and inconsistent results obtained in the above in vitro assessments of NSAIDs. From the present study we may conclude that although indomethacin and diclofenac showed an inhibitory effect on proteoglycan secretion at 50 and 100 ytg/ml, such concentrations would be in excess of those achieved in synovial fluid during normal therapeutic administration of these drugs to arthritic patients.15 16 The effects of tiaprofenic acid and ketoprofen on the secretion of proteoglycan by chondrocytes were essentially similar in our experiments. These two drugs are structurally related in that the benzene ring attached to the 2 position of propionic acid in ketoprofen is replaced by a thiophene ring in tiaprofenic acid. As the aromatic character of thiophenes is high it is perhaps not unexpected that these two drugs should behave similarly.
Tiaprofenic acid and, especially, ketoprofen had comparatively weak inhibitory effects on proteoglycan secretion. The effect was inconsistent and was not strongly dependent on concentration (see Figs 5 and 6) . Inhibition of proteoglycan secretion by high doses of these drugs was most evident during days 2-4, after which the percentage inhibition at 50 and 100 ig/ml diminished with time. Tiaprofenic acid at 10 ig/ml, a concentration which is achieved clinically in serum and synovial fluid,'7 significantly depressed proteoglycan secretion during the initial culture interval, but the effect was very slight and was transient. Studies by other workers have assessed the in vitro effects of tiaprofenic acid on murine patella cartilage,'8 canine articular cartilage explants,'9 and chick20 and rabbit'6 chondrocyte cultures. In none of these studies was a significant inhibition of proteoglycan synthesis reported, but these investigations did not include concentrations of tiaprofenic acid as high as 50 and 100 ,ug/ml, which were found to be inhibitory in the present study. de Vries et al reported that tiaprofenic acid at 30 ltg/ml did not suppress glycosaminogl can synthesis by murine patella cartilage in vitro, 8 but the explanted patellae were exposed to the drug for only 30 minutes, so the acute response to the drug measured by these authors could not be compared with our study, which may be considered as equivalent to a chronic effect.
The two sulphated polysaccharides studied, glycosaminoglycan polysulphate ester and sodium pentosan polysulphate, represent a relatively new class of antiarthritic agents, whose pharmacological properties have been recently reviewed.' 21 Their effects on chondrocyte proteoglycan secretion were, correspondingly, quite different from those of the NSAIDs. During the initial period of exposure (days 0-2) proteoglycan secretion was significantly suppressed by concentrations of 50 and 100 tLg/ml of both drugs. Although this pattern was maintained for sodium pentosan polysulphate, glycosaminoglycan polysulphate ester was not inhibitory at any concentration during the subsequent culture intervals. The significant and substantial stimulation of proteoglycan secretion in the presence of low concentrations of both these sulphated polysaccharides, once established, persisted for the duration of the experiment. This result is in contrast with the effects of the NSAIDs, none of which caused any significant stimulation of proteoglycan secretion over the concentration range examined. Our findings that sulphated polysaccharides could stimulate pro-teoglycan secretion are consistent with other reports where chondrocyte cultures were employed.22 23 The stimulation of proteoglycan secretion by these drugs in this study occurred at concen-trations which could be readily achieved in cartilage during human administration of drugs to patients for the treatment of osteoarthritis.24 Our in vitro findings are therefore consistent also with the chondroprotective action of these drugs reported to occur in a number of animal models. ' 21 The simple method used in the present study appears to offer distinct advantages over existing procedures. By reducing the tedium and experimental variability associated with other methods it has facilitated the evaluation of the effects of drugs on chondrocyte proteoglycan biosynthesis under a variety of conditions. This method should therefore find application not only in the screening of antiarthritic drugs but also in other areas where knowledge of proteoglycan biosynthesis in cell or organ cultures is an experimental objective.
